By David Sachs

 

Roche aims to buy Carmot Therapeutics, a California-based pharmaceutical firm developing drugs to treat obesity and diabetes.

The Swiss pharmaceutical company said it has entered an agreement to acquire the private company for $2.7 billion with additional payments of up to $400 million based on drug-development milestones.

The deal would give Roche access to Carmot's research-and-development portfolio, including all clinical and pretrial assets, Roche said. The portfolio includes drugs in development to treat obesity as well as type-1 and type-2 diabetes, Roche said.

Roche expects to close the transaction in the first quarter of 2024.

 

Write to David Sachs at david.sachs@wsj.com

 

(END) Dow Jones Newswires

December 04, 2023 01:32 ET (06:32 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.